Trialbee has announced the release of HIVE, a smart data science application applied on Real World Data aiming to enhance targeting and precision in performance-driven patient recruitment for global clinical trials.
“Traditional patient recruitment has limited access to patients and takes a long time to accomplish. Digital advertising for clinical trials, to supplement the pool of patients available to investigators, often results in large burdensome screening activities for the sites only to result in a few additional patients to enroll. Trialbee HIVE uses a smart modeling technique and expands the pool of potential clinical trial participants and then narrows down the pool to only the most relevant candidates matching the study criteria,” said Lollo Eriksson, Chief Strategy Officer at Trialbee.
For more information, click here.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Arcus’ Quemliclustat Earns Orphan Drug Designation as Phase III Pancreatic Cancer Trial Advances
July 11th 2025The FDA has granted orphan status to Arcus Biosciences’ CD73 inhibitor quemliclustat for metastatic pancreatic cancer, as the global PRISM-1 Phase III trial nears full enrollment following promising survival data from ARC-8.
QWINT-1 Trial: Once-Weekly Efsitora Matches Daily Glargine in Type 2 Diabetes Management
July 10th 2025Results from the Phase III QWINT-1 trial show that Eli Lilly’s once-weekly insulin efsitora is noninferior to once-daily glargine in reducing HbA1c among insulin-naïve adults with type 2 diabetes, offering a simplified fixed-dose regimen with fewer hypoglycemic events and less treatment burden.